WaveMan
WaveMan · Company
MAZE · Maze Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MAZE Maze Therapeutics (MAZE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001842295
Quote by TradingView
Form 144 · 10
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
105
13F, latest reported quarter
Conversions, 180 days
13
Codes C/M, not in net · $1.3M priced

What the filings say about MAZE

Insiders, 180 days
-$9.2M net sold
4 sellers · 12% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.3M
10 notices

Maze Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Maze Therapeutics, Inc. insiders sold a net $9.2M of stock across 93 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Bernstein Harold
President, R&D & CMO
SELL
2026-10-02 SECtraded 2026-10-01
16,141
$434.7K
+17.6%
Context
  • 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Sep 4, 2026.
  • 3 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, R&D & CMO Bernstein Harold sold about $434.7K of MAZE under a 10b5-1 plan on Oct 1, 2026; 3 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
Coloma Jason V
Chief Executive Officer
SELL
2026-10-02 SECtraded 2026-10-01
2,593
$70.1K
+17.6%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Sep 3, 2026.
  • The trade is 16.7% of the 15,558 shares held after it.
  • 3 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Coloma Jason V sold about $70.1K of MAZE under a 10b5-1 plan on Oct 1, 2026; 3 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
Coloma Jason V
Chief Executive Officer
SELL
2026-10-02 SECtraded 2026-10-01
31,908
$862.2K
+17.6%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Sep 3, 2026.
  • The trade is 16.7% of the 191,447 shares held after it.
  • 3 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Coloma Jason V sold about $862.2K of MAZE under a 10b5-1 plan on Oct 1, 2026; 3 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
Dandekar Atul
CSBO
SELL
2026-10-01 SECtraded 2026-09-29
7,500
$202.9K
+17.6%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Sep 3, 2026.
  • The trade is 23.2% of the 32,316 shares held after it.
  • 3 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CSBO Dandekar Atul sold about $202.9K of MAZE under a 10b5-1 plan on Sep 29, 2026; 3 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
Bernstein Harold
President, R&D & CMO
SELL
2026-09-08 SECtraded 2026-09-04
9,705
$254.5K
+26.4%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Sep 3, 2026.
  • 3 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, R&D & CMO Bernstein Harold sold about $254.5K of MAZE under a 10b5-1 plan on Sep 4, 2026; 3 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
93 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 88 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$9.2M over 180 days
-$4.7M over 90 days
below 83% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
105 funds bought in last quarter
more than 71% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-78.3% net margin
below 55% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.8% of the float short (float per yahoo 2026-10-26) · 6.1 days to cover · settled 2026-09-30
more than 77% of Pharma & Biotech
What changed in the last 30 days
Oct 2Chief Executive Officer Coloma Jason V sold $932.3K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2President, R&D & CMO Bernstein Harold sold $434.7K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer Coloma Jason V filed to sell $933.3K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Officer HAROLD BERNSTEIN filed to sell $438.7K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1CSBO Dandekar Atul sold $202.9K under a 10b5-1 plan (Sep 29)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch MAZE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+3.9%12M
-25%+8%+41%+73%2025-102025-122026-022026-042026-062026-082026-10 2025-12-29 · Dandekar Atul sold $2.7M2026-03-10 · Bernstein Harold sold $1.5M2025-12-29 · Bernstein Harold sold $1.1M2026-01-07 · Sohn Catherine A. sold $1.1M2026-01-07 · Bernstein Harold sold $1.0M2026-07-01 · Coloma Jason V sold $907.9K2026-10-01 · Coloma Jason V sold $862.2K2026-08-03 · Coloma Jason V sold $809.5K2025-12-29 · Bernstein Harold sold $704.0K2026-05-26 · Coloma Jason V sold $665.6K2026-06-23 · Coloma Jason V sold $621.7K2026-08-13 · Bernstein Harold sold $445.6K2026-10-01 · Bernstein Harold sold $434.7K2026-07-01 · Bernstein Harold sold $400.5K2026-05-14 · Bernstein Harold sold $393.3K2026-02-02 · Bernstein Harold sold $383.8K2025-12-29 · Bachrodt Amy sold $381.1K2026-06-01 · Bernstein Harold sold $338.9K2026-04-01 · Bernstein Harold sold $331.9K2026-03-20 · Bernstein Harold sold $297.0K2026-09-03 · Coloma Jason V sold $293.5K2026-02-02 · Bernstein Harold sold $275.3K2026-09-02 · Coloma Jason V sold $259.9K2026-09-04 · Bernstein Harold sold $254.5K2026-03-20 · Bernstein Harold sold $252.3K2025-12-29 · Dandekar Atul sold $248.2K2026-01-22 · Bachrodt Amy sold $227.6K2026-06-29 · Dandekar Atul sold $210.2K2026-08-28 · Dandekar Atul sold $206.8K2026-09-29 · Dandekar Atul sold $202.9K2025-12-30 · Bachrodt Amy sold $200.4K2026-05-29 · Dandekar Atul sold $197.6K2026-03-30 · Dandekar Atul sold $196.3K2026-07-29 · Dandekar Atul sold $193.9K2026-04-29 · Dandekar Atul sold $190.3K2026-03-20 · Bernstein Harold sold $187.2K2026-02-02 · Bachrodt Amy sold $187.1K2026-01-02 · Bernstein Harold sold $179.2K2026-02-27 · Dandekar Atul sold $172.0K2026-02-27 · Dandekar Atul sold $168.7K2026-03-02 · Bachrodt Amy sold $168.2K2026-06-01 · Coloma Jason V sold $159.6K2026-10-01 · HAROLD BERNSTEIN filed to sell $438.7K2026-10-01 · Coloma Jason V filed to sell $933.3K2026-09-04 · HAROLD BERNSTEIN filed to sell $251.1K2026-09-02 · Harold Bernstein filed to sell $283.5K2026-09-02 · Jason V Coloma filed to sell $623.4K2026-09-02 · Courtney Phillips filed to sell $110.0K2026-09-02 · Atul Dandekar filed to sell $177.2K2026-09-01 · Coloma Jason V filed to sell $908.1K2026-08-03 · Coloma Jason V filed to sell $922.6K2026-07-29 · ATUL DANDEKAR filed to sell $627.3K2026-07-01 · HAROLD BERNSTEIN filed to sell $1.4M2026-07-01 · Coloma Jason V filed to sell $1.0M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MAZE: institutional holders (13F)

13F holdings, latest reported quarter
Frazier Life Sciences Management, L.P.
5,032,915 sh
$150.2M
TRV GP IV, LLC
4,473,958 sh
$133.5M
ARCH Venture Management, LLC
4,120,053 sh
$123.0M
Deep Track Capital, LP
3,732,569 sh
$111.4M
BlackRock, Inc.
3,502,841 sh
$104.5M

Congress trades in MAZE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MAZE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
HAROLD BERNSTEIN
Filed 2026-10-01
$438.7K
Coloma Jason V
Filed 2026-10-01
$933.3K
HAROLD BERNSTEIN
Filed 2026-09-04
$251.1K
Harold Bernstein
Filed 2026-09-02
$283.5K
Jason V Coloma
Filed 2026-09-02
$623.4K

MAZE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$7.9M position · as of 2026-06-30
1.9%
PROFUND VP PHARMACEUTICALS
$206.8K position · as of 2026-06-30
1.8%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$257.1K position · as of 2026-07-31
1.2%
ALPS Medical Breakthroughs ETF
$1.3M position · as of 2026-05-31
0.8%
Virtus Biotech Clinical Trials Etf
$347.9K position · as of 2026-07-31
0.7%
JPMorgan Small Cap Growth Fund
$12.6M position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Phase 2
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $9.2M sold by insiders over 180 days, 105 funds added last quarter, $5.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MAZE financials

Net margin
-78.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$106.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.09x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-2.73x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-37.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-32.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-36.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.6B
market value at close 2026-10-26 on 2026-08-05 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-6.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Revenuen/a$167.5M
Operating income-$142.9M$57.6M
Net income-$131.1M$52.2M
EPS (diluted)-3.051.25
Operating cash flow-$111.9M$76.0M
Cash$189.2M$196.8M
SEC XBRL, fiscal years, as known on 2026-10-28

MAZE Stock Sonar score 5/7 axes

Find similar shapesCompare

MAZE ranks highest on institutional and government (71st percentile) and profitability (61st), and lowest on insider conviction (8th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
61
Inputs
  • Return on equity-37.3% · 62 pct, sector of 545
  • Return on assets-32.0% · 59 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-36.8% · 63 pct, sector of 576
Financial health
47
Inputs
  • Debt to equity0.09x · 56 pct, sector of 352
  • Cash flow to debt-2.73x · 39 pct, sector of 371
Insider conviction
8
Inputs
  • Net Form 4 buying (codes P and S), 180d-$7.2M · 16 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
71
Inputs
  • Funds adding, latest quarter105 · 71 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
48
Inputs
  • Short interest, % of float+17.8% · 19 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+6.3% · 76 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MAZE filings, in plain words

Are Maze Therapeutics insiders buying or selling MAZE?

In the 180 days to 2026-10-28, Maze Therapeutics insiders were net sellers, a net $9.2M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of MAZE?

Yes. 10 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $5.3M of stock; the latest, by HAROLD BERNSTEIN, was filed 2026-10-01.

Read the full summary

In the 180 days to 2026-10-28, Maze Therapeutics insiders were net sellers of MAZE, a net $9.2M across purchases and sales reported on Form 4 by 4 sellers. 12% of the 49 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 10 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $5.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies